From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer

César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; David Hardisson; Andrés Redondo

doi:10.1517/13543784.2011.571202

From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer

César Gómez-Raposo, Marta Mendiola, Jorge Barriuso, David Hardisson, Andrés Redondo

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Epithelial ovarian carcinoma (EOC) is the most important cause of gynecological cancer-related mortality in Western societies. The majority of patients with ovarian cancer present with advanced disease, and in this group of patients, the median survival time is only 3 years. New treatment approaches are, therefore, required to improve outcome in this disease. Two strategies have emerged with promising results: poly ADP-ribose polymerase enzyme (PARP) inhibitors and targeting angiogenesis. The challenge remains to develop a convenient and accurate method to identify patients likely to benefit from targeted therapy.

Original language	English
Pages (from-to)	591-4
Number of pages	4
Journal	Expert Opinion on Investigational Drugs
Volume	20
Issue number	5
DOIs	https://doi.org/10.1517/13543784.2011.571202
Publication status	Published - May 2011

Keywords

Angiogenesis Inhibitors/therapeutic use
Female
Humans
Molecular Targeted Therapy/methods
Neoplasms, Glandular and Epithelial/blood supply
Ovarian Neoplasms/blood supply
Poly(ADP-ribose) Polymerase Inhibitors
Precision Medicine/methods

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/13543784.2011.571202

Cite this

@article{2022d0c8e8f244ffb83585b1931f831a,

title = "From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer",

abstract = "Epithelial ovarian carcinoma (EOC) is the most important cause of gynecological cancer-related mortality in Western societies. The majority of patients with ovarian cancer present with advanced disease, and in this group of patients, the median survival time is only 3 years. New treatment approaches are, therefore, required to improve outcome in this disease. Two strategies have emerged with promising results: poly ADP-ribose polymerase enzyme (PARP) inhibitors and targeting angiogenesis. The challenge remains to develop a convenient and accurate method to identify patients likely to benefit from targeted therapy.",

keywords = "Angiogenesis Inhibitors/therapeutic use, Female, Humans, Molecular Targeted Therapy/methods, Neoplasms, Glandular and Epithelial/blood supply, Ovarian Neoplasms/blood supply, Poly(ADP-ribose) Polymerase Inhibitors, Precision Medicine/methods",

author = "C{\'e}sar G{\'o}mez-Raposo and Marta Mendiola and Jorge Barriuso and David Hardisson and Andr{\'e}s Redondo",

year = "2011",

month = may,

doi = "10.1517/13543784.2011.571202",

language = "English",

volume = "20",

pages = "591--4",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer

AU - Gómez-Raposo, César

AU - Mendiola, Marta

AU - Barriuso, Jorge

AU - Hardisson, David

AU - Redondo, Andrés

PY - 2011/5

Y1 - 2011/5

N2 - Epithelial ovarian carcinoma (EOC) is the most important cause of gynecological cancer-related mortality in Western societies. The majority of patients with ovarian cancer present with advanced disease, and in this group of patients, the median survival time is only 3 years. New treatment approaches are, therefore, required to improve outcome in this disease. Two strategies have emerged with promising results: poly ADP-ribose polymerase enzyme (PARP) inhibitors and targeting angiogenesis. The challenge remains to develop a convenient and accurate method to identify patients likely to benefit from targeted therapy.

AB - Epithelial ovarian carcinoma (EOC) is the most important cause of gynecological cancer-related mortality in Western societies. The majority of patients with ovarian cancer present with advanced disease, and in this group of patients, the median survival time is only 3 years. New treatment approaches are, therefore, required to improve outcome in this disease. Two strategies have emerged with promising results: poly ADP-ribose polymerase enzyme (PARP) inhibitors and targeting angiogenesis. The challenge remains to develop a convenient and accurate method to identify patients likely to benefit from targeted therapy.

KW - Angiogenesis Inhibitors/therapeutic use

KW - Female

KW - Humans

KW - Molecular Targeted Therapy/methods

KW - Neoplasms, Glandular and Epithelial/blood supply

KW - Ovarian Neoplasms/blood supply

KW - Poly(ADP-ribose) Polymerase Inhibitors

KW - Precision Medicine/methods

U2 - 10.1517/13543784.2011.571202

DO - 10.1517/13543784.2011.571202

M3 - Article

C2 - 21452927

SN - 1354-3784

VL - 20

SP - 591

EP - 594

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 5

ER -

From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this